Capital Advantage Inc. Has $958,000 Stake in Johnson & Johnson (NYSE:JNJ)

27 May 2020, 12:42 by Kim Johansen

Capital Advantage Inc. boosted its holdings in shares of Johnson & Johnson (NYSE:JNJ) by 2.2% during the 1st quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 6,305 shares of the company’s stock after buying an additional 138 shares during the quarter. Capital Advantage Inc.’s holdings in Johnson & Johnson were worth $958,000 at the end of the most recent quarter.

Other institutional investors have also bought and sold shares of the company. Geode Capital Management LLC lifted its stake in shares of Johnson & Johnson by 3.7% in the fourth quarter. Geode Capital Management LLC now owns 38,393,079 shares of the company’s stock valued at $5,589,167,000 after buying an additional 1,364,028 shares during the period. Bank of New York Mellon Corp increased its holdings in shares of Johnson & Johnson by 3.2% during the fourth quarter. Bank of New York Mellon Corp now owns 32,846,195 shares of the company’s stock worth $4,791,274,000 after buying an additional 1,021,877 shares in the last quarter. Norges Bank acquired a new stake in shares of Johnson & Johnson during the fourth quarter worth approximately $4,139,107,000. Massachusetts Financial Services Co. MA increased its holdings in shares of Johnson & Johnson by 3.5% in the fourth quarter. Massachusetts Financial Services Co. MA now owns 27,407,188 shares of the company’s stock valued at $3,997,886,000 after purchasing an additional 915,066 shares in the last quarter. Finally, FMR LLC increased its holdings in shares of Johnson & Johnson by 4.7% in the fourth quarter. FMR LLC now owns 17,945,766 shares of the company’s stock valued at $2,617,750,000 after purchasing an additional 799,194 shares in the last quarter. 68.45% of the stock is currently owned by hedge funds and other institutional investors.

JNJ has been the topic of a number of recent analyst reports. Citigroup lifted their price target on shares of Johnson & Johnson from $150.00 to $165.00 and gave the stock a “buy” rating in a research report on Wednesday, April 15th. Bank of America raised shares of Johnson & Johnson from a “neutral” rating to a “buy” rating and lifted their price target for the stock from $150.00 to $175.00 in a research report on Wednesday, April 22nd. Argus reissued a “buy” rating and set a $155.00 price target (down from $165.00) on shares of Johnson & Johnson in a research report on Friday, March 27th. Barclays lifted their price target on shares of Johnson & Johnson from $173.00 to $182.00 and gave the stock an “overweight” rating in a research report on Wednesday, April 29th. Finally, SVB Leerink reduced their price target on shares of Johnson & Johnson from $172.00 to $160.00 and set an “outperform” rating on the stock in a research report on Wednesday, April 8th. Four equities research analysts have rated the stock with a hold rating and thirteen have issued a buy rating to the company’s stock. The company currently has a consensus rating of “Buy” and an average target price of $163.47.

In related news, Director William D. Perez acquired 500 shares of the stock in a transaction that occurred on Friday, March 13th. The stock was acquired at an average cost of $127.69 per share, for a total transaction of $63,845.00. Following the transaction, the director now directly owns 16,030 shares in the company, valued at $2,046,870.70. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Corporate insiders own 0.27% of the company’s stock.

JNJ opened at $144.56 on Wednesday. The stock has a market capitalization of $380.36 billion, a P/E ratio of 19.12, a P/E/G ratio of 3.14 and a beta of 0.71. Johnson & Johnson has a 12 month low of $109.16 and a 12 month high of $157.00. The firm’s fifty day simple moving average is $147.76 and its 200 day simple moving average is $142.57. The company has a current ratio of 1.31, a quick ratio of 1.05 and a debt-to-equity ratio of 0.41.

Johnson & Johnson (NYSE:JNJ) last released its quarterly earnings data on Tuesday, April 14th. The company reported $2.30 earnings per share for the quarter, topping the consensus estimate of $2.03 by $0.27. Johnson & Johnson had a net margin of 24.47% and a return on equity of 39.71%. The company had revenue of $20.69 billion for the quarter, compared to analyst estimates of $19.48 billion. During the same period in the previous year, the business earned $2.10 EPS. Johnson & Johnson’s revenue for the quarter was up 3.3% compared to the same quarter last year. On average, equities research analysts predict that Johnson & Johnson will post 7.68 EPS for the current fiscal year.

The company also recently declared a quarterly dividend, which will be paid on Tuesday, June 9th. Stockholders of record on Tuesday, May 26th will be issued a dividend of $1.01 per share. This represents a $4.04 dividend on an annualized basis and a dividend yield of 2.79%. The ex-dividend date is Friday, May 22nd. This is an increase from Johnson & Johnson’s previous quarterly dividend of $0.95. Johnson & Johnson’s dividend payout ratio is 46.54%.

Johnson & Johnson Company Profile

Johnson & Johnson, together with its subsidiaries, researches and develops, manufactures, and sells various products in the health care field worldwide. It operates in three segments: Consumer, Pharmaceutical, and Medical Devices. The Consumer segment offers baby care products under the JOHNSON'S brand; oral care products under the LISTERINE brand; beauty products under the AVEENO, CLEAN & CLEAR, DABAO, JOHNSON'S Adult, LE PETITE MARSEILLAIS, NEUTROGENA, and OGX brands; over-the-counter medicines, including acetaminophen products under the TYLENOL brand; cold, flu, and allergy products under the SUDAFED brand; allergy products under the BENADRYL and ZYRTEC brands; ibuprofen products under the MOTRIN IB brand; and acid reflux products under the PEPCID brand.